Category Archives: Business and Investments

Latest From Business and Investments

The Evolution of BIO Partnering

I joined BIO in the summer of 2008, just as the global biotechnology community headed towards sunny San Diego.  This was my first experience with the scale of partnering that occurs at that meeting.  Constantly trying to be on the forefront of innovation, the BIO BD team has put forth an increased effort into converting their partnering software form a utilitarian piece of software into something that is much more. The last 18 months have Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , ,

Sector Performance Since the 2007 Market Peak

How does the biotech sector performance rank against the 10 S&P sectors since the S&P500 peak back on October 9th, 2007? As of January 6th, 2010, the Nasdaq Biotech Index (NBI) outperformed all 10 sectors, including the overall healthcare sector and the other traditionally defensive sectors: utilities and consumer staples. The AMEX Biotech Index (BTK) had some unique events in 2009 that helped it not only outperform every sector, but remain in double digit positive Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: ,

ISO: Biotech Humanitarian

We are looking for biotech humanitarians for our annual Biotech Humanitarian Award. The award recognizes an everyday hero who has helped to heal, fuel or feed the planet through their work in biotechnology. Know someone that you feel should be recognized for their good works? Nominate someone at www.iambiotech.org/award through January 31, 2010. 2009 Biotech Humanitarian Dr. Jay Keasling, was nominated by a colleague at the University of California at Berkley. Just think, you or your Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , ,

Risk/Reward Favored Small & Micro Caps in 2009

For US biotechs in 2009, the smaller the company’s market capitalization, the higher the return…

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: ,

2009 – A Big Year for the BTK

The Amex Biotech Index, the BTK, outpaced its peer, the Nasdaq Biotech Index, by 29% and was 22% above the SP500.   Most of this can be attributed to 3rd quarter performance when Human Genome Sciences (HGSI) released P3 data for their antibody drug for Lupus. HGSI gained 555% in 3Q09, and the impact on the 20 company BTK can be seen in the lower bar chart. * *It should be noted that both major Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , ,